Countdown to Interim Analysis, page-152

I hate to be that guy, but it's apoptosis, with an extra "p".

As to insurance providers, he's speaking about health insurers in the US already anticipating FDA approval for Ryoncil and Revascor (as evidenced by documents they have produced, noting when the treatment is applicable).

This indicates at least THEIR expectation that those treatments may be approved for their respective diseases in the near term. I would argue it is NOT material and need not be reported to the market, but does indicate a much higher level of industry awareness for the treatments, their current stage of review in the approval process, and to a slight degree, their sense that it's reasonably likely they will be approved. Very positive, but NOT market moving and not price sensitive.

Just another "tick" for those of us that read every single tea leaf to try to discern where things are at.